Selank
Peptide with anxiolytic claims largely from limited/region-specific clinical literature; evidence quality varies.
constraint:not-drug-test-safeevidence:lowform:othermicro:calmmicro:sleep-calmmicro:stresspop:clinical-populationsstudy:other-unclear
Dosing model
FLATFixed dose (no body-weight scaling).
Min dose
—
Max dose
—
Rounding
—
Stacks containing Selank
Public community stacks that include this ingredient.
sleepcalmfocus
Non-stimulant cognitive/calm pairing commonly discussed in nootropic communities.
Selank
1mg
New
Evidence
2 records
Anxiety symptom measures
Patients with generalized anxiety disorder/neurasthenia (reported clinical study) • Clinical-biological study (older literature)
Clinical literature reports anxiolytic effects in patient cohorts, but study designs and reporting standards vary and limit certainty.
Dose: —
Anxiolytic effect vs. phenazepam in anxiety disorders
60 patients with phobic-anxiety and somatoform disorders • Comparative clinical study
Selank showed pronounced anxiolytic and mild nootropic effects compared with phenazepam; the anxiolytic effect persisted for approximately one week after the last dose. Methodology reflects older Russian clinical reporting standards, limiting generalizability.
Dose: —
Forms
Lyophilized powder
Research material (vendor listing)